Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04337515 · ClinicalTrials.gov registry record · NA

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

A NA study of Graft-Versus-Host Disease and Graft Vs Host Disease, sponsored by Christopher Dvorak.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT04337515 is a NA study of Graft-Versus-Host Disease and Graft Vs Host Disease that is actively recruiting participants, run by Christopher Dvorak. The registered enrollment target is 90 participants, above the 80-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (13% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04337515, a NA study of Graft-Versus-Host Disease and Graft Vs Host Disease, is actively recruiting participants, sponsored by Christopher Dvorak.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD). In certain clinical situations, the optimal approach to minimize the risk of GVHD is to perform ex vivo alpha-beta T-cell depletion of the donor cells. However, the CliniMACS® Device is FDA-approved only for a narrow indication. All other uses of ex vivo processed cells must be done under a feasibility study protocol.

Interventions

  • DEVICE CliniMacs®

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2019-12-19
Est. Completion 2035-01-01
Phase NA

Sponsor

Christopher Dvorak

1 total trials

What the Registry Record Tells You About NCT04337515

The ClinicalTrials.gov registry entry for NCT04337515 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 80-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (13% higher). The listed sponsor is Christopher Dvorak, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 1 intervention - of which CliniMacs® is the first listed.

NCT04337515 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04337515 about?

NCT04337515 is a clinical study titled "A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant". Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD). In certain clinical situations, the optimal approach to minimize the risk of GVHD is to perform ex vivo alpha-beta T-cell depletion of the donor cells. However, the Clini...

What is the current status of trial NCT04337515?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2019-12-19. Estimated completion is 2035-01-01.

What conditions does trial NCT04337515 study?

This clinical trial studies the following conditions: Graft-Versus-Host Disease, Graft Vs Host Disease.

What interventions are being tested in trial NCT04337515?

The interventions under investigation include: CliniMacs® (DEVICE).

Who is sponsoring clinical trial NCT04337515?

This trial is sponsored by Christopher Dvorak, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04337515 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Graft-Versus-Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.